precision medicine

  •   George Lundberg, MD

    Endometrial cancer is the most common kind of uterine cancer. The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their most recent guideline for people with endometrial cancer.

    .

  •   Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Results from the Know Your Tumor program shows overall survival benefit for patients with an actionable alteration and who received a matched therapy, compared to those with an actionable alteration and who did not receive a matched therapy. 

    .

  •   Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Learn about Precision Promise, an adaptive multi-site clinical trial spearheaded by the Pancreatic Cancer Action Network.

    .

  •   Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: A new clinical trial is using precision medicine to identify the best individualized standard-of-care options for pancreatic cancer patients.

    .

  •   George Lundberg, MD

    Research paper from JAMIA Open curated by Editor in Chief George Lundberg, MD, who notes: 

    This study found a virtual molecular tumor board to be efficient and effective for more than 1,000 patients.

    Go to full paper published in JAMIA Open.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  
  •  
  •  

    Accuracy and Precision Define Radiation Oncology

    With: Eddy Yang, MD, PhD

    A Q&A with Eddy Yang, MD, PhD, Professor and Vice Chair of Translational Sciences Department of Radiation Oncology; Deputy Director, Associate Director of Precision Oncology at the Hugh Kaul Precision Medicine Institute; Birmingham, AL; shyang@uabmc.edu Originally published December 5, 2017 Q: You are a radiation oncologist with a particular interest in cancer of the prostate. How does the molecular study of prostate, as well… Read more »

  •  

    Why the 21st Century Cures Act is a Good Thing

    With: Mary Woolley

    A Q&A with Mary Woolley, President and CEO of Research!America Q: You attended the December 2016 signing by President Obama of the 21st Century Cures Act and are recognized to be a strong supporter. Yet harsh criticism of it has quickly appeared in JAMA, BMJ, a variety of other venues, as well as on these pages. Please tell our readers why this is good legislation… Read more »

  •